Hosted on MSN

Oppenheimer Initiates Coverage of Atai Life Sciences N.V. (ATAI) with Outperform Recommendation

Fintel reports that on July 29, 2025, Oppenheimer initiated coverage of Atai Life Sciences N.V. (NasdaqGM:ATAI) with a Outperform recommendation. Analyst Price Forecast Suggests 201.20% Upside As of ...
Nasdaq

ATAI January 2026 Options Begin Trading

Investors in ATAI Life Sciences NV (Symbol: ATAI) saw new options begin trading today, for the January 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...
Finanznachrichten

atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT

- atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023. - VLS-01 is a synthetic form of N,N-dimethyltryptamine (DMT) ...
Finanznachrichten

Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements - FinanzNachrichten.de

• Apeiron and other key shareholders enter into voluntary lock-up agreements • This voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investors • ...
Investing

atai Life Sciences reshuffles top brass, advances clinical trials

NEW YORK and BERLIN - atai Life Sciences (NASDAQ:ATAI), a biopharmaceutical company focused on mental health treatments with a market capitalization of $272 million, announced significant changes to ...